Cue Biopharma Announces Strategic Research Collaboration with Albert Einstein College of Medicine to Further the Potential of Immuno-STAT™ Platform in Chronic Infectious Diseases
Cue Biopharma, Inc. (CUE)
US:NASDAQ Investor Relations:
cuebiopharma.gcs-web.com/news-releases
Company Research
Source: GlobeNewswire
Collaboration Expands Platform’s Reach Beyond Cancer and Autoimmune Disease to Address T cell Exhaustion in Chronic Infectious Diseases CAMBRIDGE, Mass., Oct. 17, 2018 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc., (NASDAQ: CUE) an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat cancer, autoimmune and chronic infectious diseases, announced today that the company has entered into a strategic research collaboration with Albert Einstein College of Medicine to advance the next generation of Immuno-STAT™ biologics for chronic infectious diseases. “We are very pleased to expand our relationship with Albert Einstein College of Medicine, and believe this collaboration will enhance our capabilities and capacity to study and develop Immuno-STAT™ biologics to address T cell exhaustion,” said Daniel Passeri, M.Sc., J.D., President and Chief Executive Officer of Cue Biopharma. “This strategic col
Show less
Read more
Impact Snapshot
Event Time:
CUE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CUE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CUE alerts
High impacting Cue Biopharma, Inc. news events
Weekly update
A roundup of the hottest topics
CUE
News
- Here's Why Cue Biopharma (CUE) is Poised for a Turnaround After Losing -22.83% in 4 Weeks [Yahoo! Finance]Yahoo! Finance
- Cue Biopharma to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Cue Biopharma to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingGlobeNewswire
- Here's Why Cue Biopharma (CUE) Is a Great 'Buy the Bottom' Stock Now [Yahoo! Finance]Yahoo! Finance
- Cue Biopharma, Inc. (NASDAQ: CUE) had its "buy" rating re-affirmed by analysts at Stifel Nicolaus. They now have a $8.00 price target on the stock.MarketBeat
CUE
Earnings
- 8/8/23 - Beat
CUE
Sec Filings
- 4/26/24 - Form DEF
- 4/26/24 - Form DEFA14A
- 4/26/24 - Form ARS
- CUE's page on the SEC website